Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

Transaction highlights

Advances Alfasigma’s M&A-led global growth strategy, purposely focused on immunology and gastroenterology.

Synergy with Alfasigma’s specialty rheumatology portfolio, adding Nordic Pharma’s rheumatoid arthritis business, including the Nordimet® franchise.

Expands footprint by adding Canada and Japan; strengthens presence in Europe, with direct operations in 18 countries, with 265 employees. Adds approximately €190 million in 2025 revenue.